ATE266043T1 - Peptidanaloge des menschlichen basischen myelinproteins - Google Patents

Peptidanaloge des menschlichen basischen myelinproteins

Info

Publication number
ATE266043T1
ATE266043T1 AT95942843T AT95942843T ATE266043T1 AT E266043 T1 ATE266043 T1 AT E266043T1 AT 95942843 T AT95942843 T AT 95942843T AT 95942843 T AT95942843 T AT 95942843T AT E266043 T1 ATE266043 T1 AT E266043T1
Authority
AT
Austria
Prior art keywords
peptide analogues
myelin protein
human basic
peptide
basic myelin
Prior art date
Application number
AT95942843T
Other languages
English (en)
Inventor
Nicholas Ling
Amitabh Gaur
Paul J Conlon
Lawrence Steinman
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Application granted granted Critical
Publication of ATE266043T1 publication Critical patent/ATE266043T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95942843T 1994-11-18 1995-11-16 Peptidanaloge des menschlichen basischen myelinproteins ATE266043T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/342,408 US6329499B1 (en) 1994-11-18 1994-11-18 Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
PCT/US1995/014403 WO1996016086A1 (en) 1994-11-18 1995-11-16 Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein

Publications (1)

Publication Number Publication Date
ATE266043T1 true ATE266043T1 (de) 2004-05-15

Family

ID=23341698

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95942843T ATE266043T1 (de) 1994-11-18 1995-11-16 Peptidanaloge des menschlichen basischen myelinproteins

Country Status (13)

Country Link
US (2) US6329499B1 (de)
EP (2) EP1440980A3 (de)
JP (1) JPH10509172A (de)
AT (1) ATE266043T1 (de)
AU (1) AU4405896A (de)
CA (1) CA2204147A1 (de)
DE (1) DE69532996T2 (de)
DK (1) DK0792287T3 (de)
ES (1) ES2218559T3 (de)
MX (1) MX9703643A (de)
NO (1) NO972264L (de)
PT (1) PT792287E (de)
WO (1) WO1996016086A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
BR9509438A (pt) * 1994-10-25 1997-12-23 Immulogic Pharma Corp Composições e tratamento para a esclerose múltipla
DE69525544T2 (de) * 1994-11-18 2002-08-22 Neurocrine Biosciences, Inc. Peptidanaloga des menschlichen myelinbasischen proteins mit substitution in position 91 zur behandlung von multipler sklerose
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6251396B1 (en) * 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US5874531A (en) * 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
WO1996028470A2 (en) * 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
US6737057B1 (en) 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
CA2494338C (en) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
DK1918298T3 (da) 2000-08-21 2010-11-29 Apitope Technology Bristol Ltd Peptid
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
MXPA03010037A (es) * 2001-05-01 2004-06-30 Univ California Moleculas de fusion y metodos para tratamiento de enfermedades inmunes.
WO2004032824A2 (en) 2002-10-10 2004-04-22 Yeda Research And Development Co. Ltd. Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
US7084247B2 (en) * 2004-03-11 2006-08-01 Peptimmune, Inc. Identification of self and non-self antigens implicated in autoimmune diseases
US8258099B2 (en) * 2004-07-15 2012-09-04 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Pin1-modulating compounds and methods of use thereof
US20060240032A1 (en) * 2005-03-31 2006-10-26 Hinrichs David J Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
DK2347775T3 (da) 2005-12-13 2020-07-13 Harvard College Skabeloner til celletransplantation
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
CN102006891B (zh) 2008-02-13 2017-04-26 哈佛学院董事会 连续的细胞程序化装置
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2009146456A1 (en) 2008-05-30 2009-12-03 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
US8728456B2 (en) 2009-07-31 2014-05-20 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
WO2011109834A2 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1
US9693954B2 (en) 2010-06-25 2017-07-04 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
EP3620185A1 (de) 2010-10-06 2020-03-11 President and Fellows of Harvard College Injizierbare porenbildende hydrogele für materialbasierte zelltherapien
WO2012064697A2 (en) 2010-11-08 2012-05-18 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
EP2701753B1 (de) 2011-04-27 2018-12-26 President and Fellows of Harvard College Zellfreundliche inverse und opake hydrogele zur zelleinkapselung, zur arzneimittel- und proteinabgabe sowie für funktionelle nanopartikeleinkapselung
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
ES2685327T3 (es) 2011-04-28 2018-10-08 President And Fellows Of Harvard College Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
AU2012261848B2 (en) 2011-06-03 2017-06-15 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
PT2838515T (pt) 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
EP3137105A4 (de) 2014-04-30 2017-12-27 President and Fellows of Harvard College Kombinationsimpfstoffvorrichtungen und -verfahren zur abtötung von krebszellen
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
CN114099793A (zh) 2015-04-10 2022-03-01 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
EP3484448B1 (de) 2016-07-13 2025-04-09 President and Fellows of Harvard College Antigenpräsentierende zellmimetische gerüste und verfahren zur herstellung und verwendung davon
RU2770060C2 (ru) 2016-08-02 2022-04-14 Президент Энд Феллоуз Оф Гарвард Колледж Биологические материалы для модуляции иммунных ответов
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
EP4034148A4 (de) 2019-09-23 2025-09-10 Harvard College Biomaterialbasierter antigenfreier impfstoff und verwendung davon

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340012C (en) 1987-08-17 1998-08-25 Trustees Of Leland Stanford Jr. University Peptide determinant associated with immunity
US5468481A (en) * 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
GB8915019D0 (en) * 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
DE69127470T2 (de) 1990-03-02 1998-02-19 Autoimmune Inc Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
US6077509A (en) 1990-03-30 2000-06-20 Autoimmune, Inc. Peptide fragments of myelin basic protein
ATE189230T1 (de) 1991-05-31 2000-02-15 Connetics Corp T-zell rezeptorpeptide als therapeutika für immun-verwandte krankheiten
US5817629A (en) 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
CA2053799C (en) 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
WO1993021222A1 (en) 1992-04-09 1993-10-28 Autoimmune, Inc. Suppression of t-cell proliferation using peptide fragments of myelin basic protein
JPH06157591A (ja) * 1992-11-27 1994-06-03 Teijin Ltd 抗凝固性ペプチド
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
CA2172512A1 (en) 1993-09-22 1995-03-30 Lawrence Steinman Interaction of t-cell receptors and antigen in autoimmune disease
DE69525544T2 (de) 1994-11-18 2002-08-22 Neurocrine Biosciences, Inc. Peptidanaloga des menschlichen myelinbasischen proteins mit substitution in position 91 zur behandlung von multipler sklerose
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
WO1996028470A2 (en) 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis

Also Published As

Publication number Publication date
EP0792287B1 (de) 2004-05-06
EP0792287A1 (de) 1997-09-03
JPH10509172A (ja) 1998-09-08
WO1996016086A1 (en) 1996-05-30
EP1440980A3 (de) 2005-01-19
NO972264L (no) 1997-07-16
DE69532996D1 (de) 2004-06-09
NO972264D0 (no) 1997-05-16
MX9703643A (es) 1997-08-30
PT792287E (pt) 2004-09-30
US20020086976A1 (en) 2002-07-04
DK0792287T3 (da) 2004-08-30
EP1440980A2 (de) 2004-07-28
DE69532996T2 (de) 2005-04-14
AU4405896A (en) 1996-06-17
ES2218559T3 (es) 2004-11-16
US6329499B1 (en) 2001-12-11
CA2204147A1 (en) 1996-05-30

Similar Documents

Publication Publication Date Title
DE69532996D1 (de) Peptidanaloge des menschlichen basischen myelinproteins
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
DE69525544D1 (de) Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
AP2000001888A0 (en) Method for treatment of diabetes using peptides analogues of insulin.
PT662827E (pt) Metodos de diagnostico e composicoes farmaceuticas a base de proteinas notch e acidos nucleicos
RU95115239A (ru) Аналог эритропоэтина
ATE121755T1 (de) Deletionsanaloga von magaininpeptiden.
HUT69169A (en) T-cell-suppressive peptide fragments of human myelin basic protein (hmbp) and pharmaceutical compositions containing them
GB9606040D0 (en) Active peptide
DK525384D0 (da) Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
NZ235497A (en) Peptides (possibly related to hirudin) and pharmaceutical compositions for reducing blood coagulation
DE69636052D1 (de) Mpl-liganden analoga
ES2080060T3 (es) Proteinas que tienen actividad de union a interferon-gamma.
HUT52117A (en) Process for producing amblyommin and process for producing pharmaceutical compositions comprising such compound as active ingredient
ES2062572T3 (es) Analogos de somatotropina.
ATE92078T1 (de) Pharmakologisch aktive peptide.
DE69418353D1 (de) Cyclische Pentapeptide mit Beta-Turn und Gamma-Turn
ES2023746A6 (es) Procedimiento de preparacion de peptidos de serina-acido aspartico- lisina
ATE27822T1 (de) Hexapeptid, verfahren zur herstellung und pharmazeutische zusammensetzungen hieraus.
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
DE3882233D1 (de) Gefaessaktive peptide.
ATE170873T1 (de) Bombesin-analogen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0792287

Country of ref document: EP

REN Ceased due to non-payment of the annual fee